GLP-1 Medications and PoTS: Here Is What the Evidence Says.

Today let’s decode one of the most timely intersections in chronic illness right now. GLP-1 receptor agonists, the drug class behind Ozempic, Wegovy and Mounjaro, are being prescribed legitimately, and illegitimately, to millions of people worldwide. A significant proportion of those people have PoTS, dysautonomia or Long COVID. And the emerging evidence suggests the relationship between these drugs and autonomic function is more complicated, and more interesting, than most prescribing clinicians currently realise.

What GLP-1 receptor agonists actually do

GLP-1 stands for glucagon-like peptide-1, a hormone produced in the gut after eating that stimulates insulin release, suppresses glucagon, slows gastric emptying and reduces appetite. GLP-1 receptor agonists mimic this hormone and have proven remarkably effective for blood sugar control and weight loss.

What is less well known outside specialist circles is that GLP-1 receptors are not confined to the pancreas and gut. They are found throughout the brain, in the autonomic nervous system, in the vagus nerve and in regions involved in cardiovascular regulation. This means GLP-1 agonists are not purely metabolic drugs, they have neurological and autonomic effects and in people with already dysregulated autonomic systems, those effects matter.

The case that suggests benefit

A 2026 case report (case report = one interesting case of one/ small collection of people, not a trial) published in Clinical Autonomic Research describes a patient with confirmed PoTS who was started on semaglutide (Ozempic/Wegovy) for weight management. Over the following months, their PoTS symptoms improved significantly, to a degree that surprised their treating clinician enough to write it up.

The proposed mechanism is genuinely interesting. GLP-1 receptors in the brain are involved in regulating inflammation and protecting neurons. Semaglutide, which crosses the blood-brain barrier, appears to have neuroprotective and anti-inflammatory effects in the central nervous system. Given that neuroinflammation is increasingly implicated in PoTS and Long COVID dysautonomia, this is a plausible and exciting mechanism rather than just a happy coincidence.

The same research group has previously published work on neuroinflammation at the dorsolateral inferior medulla as a possible central nervous system localisation for PoTS and Long COVID. The dots are starting to connect.

The case that suggests harm

However, a 2025 case report tells a very different story. A patient with PoTS was started on tirzepatide (Mounjaro), and their symptoms worsened dramatically. Marked tachycardia and orthostatic intolerance both increased significantly after starting the drug.

The key difference between semaglutide and tirzepatide is that tirzepatide is a dual agonist. It activates both GLP-1 receptors and GIP receptors (glucose-dependent insulinotropic polypeptide). GIP receptors are found in blood vessel walls and appear to promote vasodilation. For most people this is not a significant problem. For someone with PoTS, where blood is already pooling in the lower limbs due to inadequate vasoconstriction on standing, adding a drug that promotes vasodilation could substantially worsen orthostatic intolerance. That appears to be exactly what happened here.

The adverse event data

A 2024 analysis presented at the American College of Cardiology searched the FDA’s adverse event reporting database for cases of cardiac dysautonomia symptoms, specifically tachycardia, palpitations, dizziness and PoTS, associated with semaglutide and liraglutide. Of 35,307 total adverse event reports, 307 met criteria for cardiac dysautonomia or related symptoms. The authors concluded that both drugs have a small incidence of cardiac dysautonomia as an adverse event, the majority of which was classified as non-serious, but called for more studies.

It is important to note that adverse event databases capture reports of symptoms occurring in people taking a drug, not proof that the drug caused them. People with PoTS who are prescribed GLP-1 agonists may experience PoTS symptoms that would have occurred regardless. The signal is worth watching but should not be over-interpreted.

What this means in practice

The picture emerging is nuanced. Semaglutide, which acts only on GLP-1 receptors, may actually have beneficial effects on autonomic function in some PoTS patients through anti-inflammatory and neuroprotective mechanisms. Tirzepatide, with its additional GIP receptor activity and vasodilatory effects, may worsen orthostatic intolerance in the same population.

None of this is yet at the level of clinical guidance. Both drugs are prescribed off-label for many things, but neither is approved or recommended for PoTS specifically. If you have PoTS and are being considered for a GLP-1 agonist for weight management or diabetes, it is worth raising your autonomic history explicitly with your prescribing clinician and discussing which specific drug within this class is being proposed, because they are not interchangeable for this patient population.

If you are already on a GLP-1 agonist and notice your PoTS symptoms worsening, this research provides a plausible biological explanation and is worth discussing with your team rather than dismissing as coincidence.

The bigger picture

GLP-1 receptor agonists are increasingly being studied beyond their original metabolic indications, for neurological conditions, cardiovascular disease, addiction, and now autonomic disorders. The biology is genuinely interesting and the potential therapeutic applications are wide. For the PoTS and Long COVID community, this is an area worth watching closely, not because there is enough evidence to recommend these drugs for autonomic symptoms, but because the mechanism is plausible, the early signals are mixed in ways that are informative, and the research is moving quickly.

The views and opinions expressed in Dysautonomia Decoded are my own and do not represent those of my employer or any affiliated organisation.

References

Blitshteyn S, Suresh S, Lorenzi LM. Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report. Clinical Autonomic Research. 2026;36:315–317. https://doi.org/10.1007/s10286-026-01197-1

Katapadi A, et al. Can GLP-1 agonist for weight loss cause cardiac dysautonomia? A study of the FAERS database. JACC. 2024;83(13 Supplement):27. https://doi.org/10.1016/S0735-1097(24)02017-5

Sheth K, Kim S, Porterfield L, et al. The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes. Current Atherosclerosis Reports. 2025;27:76. https://doi.org/10.1007/s11883-025-01319-6

Blitshteyn S. Neuroinflammation at the dorsolateral inferior medulla: a possible central nervous system localization for POTS and long COVID. Clinical Autonomic Research. 2025.